1

2

3

4

5

7

8

9

10

11

12

13

14

15

16

21

22

23

24

25

26

27

28

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

55

013 6

The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States

Gillian Elizabeth Hanley, PhD; Jessica Nell McAlpine, MD; Celeste Leigh Pearce, PhD; Dianne Miller, MD

BACKGROUND: Ovarian cancer is the leading cause of death due to gynecologic malignancy and the fifth most common cause of cancer deaths in developed countries. Recent evidence has indicated that the most common and lethal form of ovarian cancer originates in the distal fallopian tube, and recommendations for surgical removal of the fallopian tube (bilateral salpingectomy) at the time of other gynecologic surgeries (particularly hysterectomy and tubal sterilization) have been made, most recently by the American Congress of Obstetricians and Gynecologists.

OBJECTIVE: We sought to assess the uptake and perioperative safety 17 of bilateral salpingectomy at the time of hysterectomy and tubal sterili-18 zation in the United States and to examine the factors associated with 19 increased likelihood of bilateral salpingectomy. 20

STUDY DESIGN: The Nationwide Inpatient Sample was used to identify Q2 all girls and women 15 years or older without gynecologic cancer who underwent inpatient hysterectomy or tubal sterilization, with and without bilateral salpingectomy, from 2008 through 2013. Weighted estimates of national rates of these procedures were calculated and the number of procedures performed estimated. Safety was assessed by examining rates of blood transfusions, perioperative complications, postprocedural infection, and fever, and adjusted odds ratios were calculated comparing hysterectomy with salpingectomy with hysterectomy alone.

29 Q3 RESULTS: We included 425,180 women who underwent inpatient 30 hysterectomy from 2008 through 2013 representing a national cohort of

Introduction

Ovarian cancer is the leading cause of death due to gynecologic malignancy and the fifth most common cause of cancer deaths in developed countries. In the United States and Canada, there are ~25,000 new diagnoses and ~16,000 deaths from the disease annually. In both general population and high-risk women (BRCA1 and BRCA2 mutation carriers), screening for ovarian cancer is not recommended, as no mortality benefit has been demonstrated even with strict adherence to screening protocols,¹⁻⁵ which has prompted a push to explore

50	Cite this article as: Hanley GE, McAlpine JN, Pearce CL,
51	et al. The performance and safety of bilateral sal-
52	pingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol 2016;volume:x.ex-x.ex.
53	

- 0002-9378/\$36.00 54
 - © 2016 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ajog.2016.10.035

methods of primary prevention. In the last decade, we have dramatically improved our understanding of the 5 main histological subtypes of ovarian carcinoma: high-grade serous cancer (HGSC), low-grade serous cancer, endometrioid cancer, clear cell cancer, and mucinous cancers. HGSC is the most common histotype, accounting for approximately 70% of invasive ovarian carcinomas,⁶ and research has demonstrated that the distal fallopian tube is the probable site of origin of the majority of HGSCs.⁷⁻¹⁰

Given these findings, recommendations were made regarding removal of the fallopian tube during common gynecologic surgeries in women who had completed childbearing. In September 2010 the ovarian cancer research team recommended to all gynecologic surgeons in the province of British Columbia, Canada, that, when operating on women at general population risk for

2,036,449 (95% confidence interval, 1,959,374-2,113,525) women. There was an increase in the uptake of hysterectomy with bilateral salpingectomy of 371% across the study period, with 7.7% of all hysterectomies including bilateral salpingectomy in 2013 (15.8% among women retaining their ovaries). There were only 1195 salpingectomies for sterilization, thus no further comparisons were possible. In the women who had hysterectomy with bilateral salpingectomy, there was no increased risk for blood transfusion (adjusted odds ratio, 0.95; 95% confidence interval, 0.86-1.05) postoperative complications (adjusted odds ratio, 0.97; 95% confidence interval, 0.88-1.07), postoperative infections (adjusted odds ratio, 1.26; 95% confidence interval, 0.90-1.78), or fevers (adjusted odds ratio, 1.33; 95% confidence interval, 1.00–1.77) compared with women undergoing hysterectomy alone. Younger age, private for-profit hospital setting, larger hospital size, and indication for hysterectomy were all associated with increased likelihood of getting a hysterectomy with bilateral salpingectomy in women retaining their ovaries.

CONCLUSION: Our results suggest that hysterectomy with bilateral salpingectomy is significantly increasing in the United States and is not associated with increased risks of postoperative complications.

Key words: bilateral salpingectomy, hysterectomy, ovarian cancer prevention, tubal sterilization, United States

> ovarian cancer, they should consider: (1) performing bilateral salpingectomy at the time of hysterectomy (even when the ovaries are being preserved); and (2) performing bilateral salpingectomy in place of tubal ligation for permanent sterilization. This was followed by a similar recommendation from the Society of Gynecologic Oncology of Canada,¹¹ and later by the Society of Gynecologic Oncology.¹² Most recently the American Congress of Obstetricians and Gynecologists (ACOG) published a statement supporting the recommendation that surgeons and patients discuss removing the fallopian tubes during a hysterectomy without oophorectomy, and consider a bilateral salpingectomy when counseling women about laparoscopic sterilization methods.¹³ Among BRCA1 and BRCA2 mutation carriers, bilateral risk-reducing salpingooophorectomy (BSO) remains the recommended prevention approach.

56

ARTICLE IN PRESS

Original Research GYNECOLOGY

ajog.org

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

111 Previous research has indicated a sig-112 nificant increase in uptake of bilateral 113 salpingectomy in the United States. 114Hicks-Courant¹⁴ reported a 77% in-115 crease in the rate of any bilateral sal-116 pingectomy in the United States from 117 2000 through 2013. Research examining 118 hysterectomy with adnexal procedures 119 reported a near quadrupling of the rate 120 of hysterectomy with bilateral sal-121 pingectomy from 1998 through 2011.¹⁵ 122 Herein, we use data from the Nation-123 wide Inpatient Sample (NIS) to present 124 national statistics on hysterectomy with 125 bilateral salpingectomy and salpingec-126 tomy for sterilization in the United 127 States from 2008 through 2013, and add 128 to the current literature by examining 129 whether there are increased rates of 130 perioperative and postoperative com-131 plications associated with bilateral sal-132 pingectomy. We also examine the factors 133 associated with having a hysterectomy 134 with bilateral salpingectomy. 135

136
137Materials and Methods

This study was conducted using the 138 Agency for Healthcare Research and 139 Quality NIS data set, which is the largest 140 publicly available all-payer inpatient care 141 database in the United States. The NIS 142 contains a random sample of approxi-143 mately 20% of discharges (>7 million 144 hospital stays annually). The NIS also 145 provide trend weights. Applying the 146 trend weights make the estimates repre-147 sentative of all hospital discharges within 148 the United States allowing for represen-149 tation of >36 million hospitalizations 150 annually and 97% of the US popula-151 tion.¹⁶ Institutional ethics approval for 152 this project was not required because it 153 fell under Article 2.4 of the "Research 154 Exempt from REB review" section of the Q4 155 TriCouncil Policy Statement: Ethical 156 Conduct for Research Involving 157 Humans 2. 158

We identified procedures using the 159 Clinical Classifications Software (CCS) 160 Q5 services and procedure categories. We 161 included all women who underwent a 162 hysterectomy (CCS code 124), tubal 163 ligation (CCS code 121), bilateral oo-164 phorectomy (CCS code 119), or bilateral 165 salpingectomy (CCS code 665) alone 166 from 2008 through 2013. Each

procedure is coded separately, so a patient undergoing a hysterectomy with BSO would have a code for each procedure. This time period was selected to represent an era prior to the launch of an educational campaign proposing salpingectomy in women at low risk for developing ovarian cancer who were undergoing other procedures, eg, hysterectomy, for the prevention of ovarian cancer (September 2010) and after, with 2013 being the last year complete data were available.¹⁷ We excluded patients who were not coded as being female, were <15 years old, or had a diagnosis of gynecologic cancer. Patients were stratified based on a combination of their CCS code (a system that categorizes patient diagnoses and procedures into a manageable number of clinically meaningful categories) and their International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. We stratified into 5 groups: (1) women who underwent hysterectomy with no concomitant oophorectomy or salpingectomy (hysterectomy alone); (2) women who underwent hysterectomy with BSO; (3) women who underwent hysterectomy and bilateral salpingectomy; (4) women who underwent tubal ligation; and (5) women who had bilateral salpingectomy alone with a diagnosis code indicating the procedure was for sterilization (ICD-9-CM V25.2). We examined the surgical approach to the hysterectomy stratifying women into 5 groups: abdominal (ICD-9-CM 68.3, 68.39, 68.4, 68.49, 68.9), laparoscopic (ICD-9-CM 68.31, 68.41, 68.51), vaginal (ICD-9-CM 68.5, 68.59), radical (ICD-9-CM 68.6, 68.61, 68.69, 68.7), and robotic (any hysterectomy code along with ICD-9-CM 17.4x). We also used diagnostic codes to examine indications for hysterectomy, including endometriosis (ICD-9-CM 617), leiomyoma (ICD-9-CM 218), benign ovarian or uterine neoplasms (ICD-9-CM 219, 220), abnormal bleeding (ICD-9-CM 626), pelvic organ prolapse (ICD-9-CM 618), pelvic inflammatory disease (ICD-9-CM 614.9), and hydrosalpinx (ICD-9-CM 614.1).¹⁸ To assess operative and perioperative complications, we examined differences in hospital length

of stay, rates of blood transfusions (*ICD-9-CM* 99.0x), complication of procedures (*ICD-9-CM* 998.x), postoperative infection (*ICD-9-CM* 998.5), and post-procedural fever (*ICD-9-CM* 780.62).

Statistical analysis

We estimated the nationally representative number of women undergoing each of our procedures of interest from 2008 through 2013 using the trend weights to facilitate comparisons across time and to report how the sample numbers reflect the national numbers.¹⁶ We calculated the percentage change in the number of each procedure performed across the study period. After examining the number of each of the procedures of interest, we decided not to pursue further comparisons between our tubal ligations and salpingectomy for sterilization groups due to very low numbers of women undergoing salpingectomy for sterilization. This may reflect the fact that many tubal sterilization procedures are done as outpatient procedures and not included in the NIS data set, which is supported by the fact that 85% of the women in our data set with a diagnostic code for sterilization had a labor and delivery code in the same hospital stay, suggesting their inpatient stay was for childbirth rather than the tubal sterilization procedure. Thus, we focused only on hysterectomy patients in more detail. We examined patient characteristics across the 3 categories of hysterectomy (hysterectomy alone, hysterectomy with BSO, and hysterectomy with bilateral salpingectomy) and used χ^2 tests to examine differences across the groups. To examine operative and perioperative complications, we ran logistic regressions adjusting for patient age, indication for hysterectomy, surgical approach, and number of chronic conditions. We obtained adjusted odds ratios (aOR) for blood transfusion, procedural complications, postoperative infection, and postprocedural fever, adjusting for patient age, indication for hysterectomy, surgical approach, and number of chronic conditions. We were unable to assess hospital readmissions because the NIS data are collected at the level of the discharge and not the patient.

1.e2 American Journal of Obstetrics & Gynecology MONTH 2016

Download English Version:

https://daneshyari.com/en/article/5676243

Download Persian Version:

https://daneshyari.com/article/5676243

Daneshyari.com